The impact of genomic changes on treatment of lung cancer von CARDARELLA, Stephanie, JOHNSON, Bruce E

Volltext

Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer von Wang, Xinan, Ricciuti, Biagio, Nguyen, Tom, Li, Xihao, Rabin, Michael S, Awad, Mark M, Lin, Xihong, Johnson, Bruce E, Christiani, David C

Volltext

Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints von Koyama, Shohei, Akbay, Esra A., Li, Yvonne Y., Herter-Sprie, Grit S., Buczkowski, Kevin A., Richards, William G., Gandhi, Leena, Redig, Amanda J., Rodig, Scott J., Asahina, Hajime, Jones, Robert E., Kulkarni, Meghana M., Kuraguchi, Mari, Palakurthi, Sangeetha, Fecci, Peter E., Johnson, Bruce E., Janne, Pasi A., Engelman, Jeffrey A., Gangadharan, Sidharta P., Costa, Daniel B., Freeman, Gordon J., Bueno, Raphael, Hodi, F. Stephen, Dranoff, Glenn, Wong, Kwok-Kin, Hammerman, Peter S.

Volltext

Dabrafenib plus trametinib in patients with previously treated BRAFV600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial von Planchard, David, MD, Besse, Benjamin, MD, Groen, Harry J M, Prof, Souquet, Pierre-Jean, MD, Quoix, Elisabeth, Prof, Baik, Christina S, MD, Barlesi, Fabrice, Prof, Kim, Tae Min, MD, Mazieres, Julien, Prof, Novello, Silvia, MD, Rigas, James R, MD, Upalawanna, Allison, PharmD, D'Amelio, Anthony M, PhD, Zhang, Pingkuan, MD, Mookerjee, Bijoyesh, MD, Johnson, Bruce E, Prof

Volltext

A single-cell landscape of high-grade serous ovarian cancer von Izar, Benjamin, Tirosh, Itay, Stover, Elizabeth H., Wakiro, Isaac, Cuoco, Michael S., Alter, Idan, Rodman, Christopher, Leeson, Rachel, Su, Mei-Ju, Shah, Parin, Iwanicki, Marcin, Walker, Sarah R., Kanodia, Abhay, Melms, Johannes C., Mei, Shaolin, Lin, Jia-Ren, Porter, Caroline B. M., Slyper, Michal, Waldman, Julia, Jerby-Arnon, Livnat, Ashenberg, Orr, Brinker, Titus J., Mills, Caitlin, Rogava, Meri, Vigneau, Sébastien, Sorger, Peter K., Garraway, Levi A., Konstantinopoulos, Panagiotis A., Liu, Joyce F., Matulonis, Ursula, Johnson, Bruce E., Rozenblatt-Rosen, Orit, Rotem, Asaf, Regev, Aviv

Volltext

MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium von Guo, Robin, Berry, Lynne D., Aisner, Dara L., Sheren, Jamie, Boyle, Theresa, Bunn, Paul A., Johnson, Bruce E., Kwiatkowski, David J., Drilon, Alexander, Sholl, Lynette M., Kris, Mark G.

Volltext

HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium von Pillai, Rathi N., Behera, Madhusmita, Berry, Lynne D., Rossi, Mike R., Kris, Mark G., Johnson, Bruce E., Bunn, Paul A., Ramalingam, Suresh S., Khuri, Fadlo R.

Volltext

Dabrafenib in patients with BRAFV600E -positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial von Planchard, David, MD, Kim, Tae Min, MD, Mazieres, Julien, Prof, Quoix, Elisabeth, Prof, Riely, Gregory, MD, Barlesi, Fabrice, Prof, Souquet, Pierre-Jean, MD, Smit, Egbert F, Prof, Groen, Harry J M, Prof, Kelly, Ronan J, MD, Cho, B C, MD, Socinski, Mark A, Prof, Pandite, Lini, MD, Nase, Christine, BSN, Ma, Bo, PhD, D'Amelio, Anthony, PhD, Mookerjee, Bijoyesh, MD, Curtis, C Martin, BS, Johnson, Bruce E, Prof

Volltext

State of the art: Response assessment in lung cancer in the era of genomic medicine von Nishino, Mizuki, Hatabu, Hiroto, Johnson, Bruce E, McLoud, Theresa C

Volltext

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs von Kris, Mark G, Johnson, Bruce E, Berry, Lynne D, Kwiatkowski, David J, Iafrate, A. John, Wistuba, Ignacio I, Varella-Garcia, Marileila, Franklin, Wilbur A, Aronson, Samuel L, Su, Pei-Fang, Shyr, Yu, Camidge, D. Ross, Sequist, Lecia V, Glisson, Bonnie S, Khuri, Fadlo R, Garon, Edward B, Pao, William, Rudin, Charles, Schiller, Joan, Haura, Eric B, Socinski, Mark, Shirai, Keisuke, Chen, Heidi, Giaccone, Giuseppe, Ladanyi, Marc, Kugler, Kelly, Minna, John D, Bunn, Paul A

Volltext

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing von Imielinski, Marcin, Berger, Alice H., Hammerman, Peter S., Hernandez, Bryan, Pugh, Trevor J., Hodis, Eran, Cho, Jeonghee, Suh, James, Capelletti, Marzia, Sivachenko, Andrey, Sougnez, Carrie, Auclair, Daniel, Lawrence, Michael S., Stojanov, Petar, Cibulskis, Kristian, Choi, Kyusam, de Waal, Luc, Sharifnia, Tanaz, Brooks, Angela, Greulich, Heidi, Banerji, Shantanu, Zander, Thomas, Seidel, Danila, Leenders, Frauke, Ansén, Sascha, Ludwig, Corinna, Engel-Riedel, Walburga, Stoelben, Erich, Wolf, Jürgen, Goparju, Chandra, Thompson, Kristin, Winckler, Wendy, Kwiatkowski, David, Johnson, Bruce E., Jänne, Pasi A., Miller, Vincent A., Pao, William, Travis, William D., Pass, Harvey I., Gabriel, Stacey B., Lander, Eric S., Thomas, Roman K., Garraway, Levi A., Getz, Gad, Meyerson, Matthew

Volltext

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC von Alessi, Joao V., Ricciuti, Biagio, Wang, Xinan, Pecci, Federica, Di Federico, Alessandro, Lamberti, Giuseppe, Elkrief, Arielle, Rodig, Scott J., Lebow, Emily S., Eicholz, Jordan E., Thor, Maria, Rimner, Andreas, Schoenfeld, Adam J., Chaft, Jamie E., Johnson, Bruce E., Gomez, Daniel R., Awad, Mark M., Shaverdian, Narek

Volltext

Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer von Wang, Xinan, Ricciuti, Biagio, Alessi, Joao V, Nguyen, Tom, Awad, Mark M, Lin, Xihong, Johnson, Bruce E, Christiani, David C

Volltext

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer von JACKMAN, David, PAO, William, RIELY, Gregory J, ENGELMAN, Jeffrey A, KRIS, Mark G, JÄNNE, Pasi A, LYNCH, Thomas, JOHNSON, Bruce E, MILLER, Vincent A

Volltext

Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting von EBERHARD, David A, GIACCONE, Giuseppe, JOHNSON, Bruce E

Volltext

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions von Oxnard, Geoffrey R., Lo, Peter C., Nishino, Mizuki, Dahlberg, Suzanne E., Lindeman, Neal I., Butaney, Mohit, Jackman, David M., Johnson, Bruce E., Jänne, Pasi A.

Volltext

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience von Sholl, Lynette M., Aisner, Dara L., Varella-Garcia, Marileila, Berry, Lynne D., Dias-Santagata, Dora, Wistuba, Ignacio I., Chen, Heidi, Fujimoto, Junya, Kugler, Kelly, Franklin, Wilbur A., Iafrate, A. John, Ladanyi, Marc, Kris, Mark G., Johnson, Bruce E., Bunn, Paul A., Minna, John D., Kwiatkowski, David J.

Volltext

ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab fo... von JOHNSON, Bruce E, KABBINAVAR, Fairooz, RUBIN, Mark, WHITE, Leonard, YANG, James Chih-Hsin, BOWDEN, Chris, MILLER, Vincent, FEHRENBACHER, Louis, HAINSWORTH, John, KASUBHAI, Saifuddin, KRESSEL, Bruce, LIN, Chin-Yu, MARSLAND, Thomas, PATEL, Taral, POLIKOFF, Jonathan

Volltext

Unique Clinicopathologic Features Characterize ALK-Rearranged Lung Adenocarcinoma in the Western Population von RODIG, Scott J, MINO-KENUDSON, Mari, JANNE, Pasi A, LYNCH, Thomas, JOHNSON, Bruce E, LAFRATE, A. John, CHIRIEAC, Lucian R, DACIC, Sanja, YEAP, Beow Y, SHAW, Alice, BARLETTA, Justine A, STUBBS, Hannah, LAW, Kenny, LINDEMAN, Neal, MARK, Eugene

Volltext

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer von Herbst, Roy S, Prager, Diane, Hermann, Robert, Fehrenbacher, Lou, Johnson, Bruce E, Sandler, Alan, Kris, Mark G, Tran, Hai T, Klein, Pam, Li, Xin, Ramies, David, Johnson, David H, Miller, Vincent A

Volltext